SELECTING AN APPROPRIATE AND REIMBURSED ANTI-OSTEOPOROTIC TREATMENT OPTION: A PRACTICAL TOOL IN THE BELGIAN SETTING

REFERENCES

• WHO Technical Report Series. Prevention and management of osteoporosis 2003.
   Google Scholar
• Jilka RL. Cytokines, bone remodeling, and oestrogen deficiency: a 1998 update. Bone 1998; 23: 75–81.
   PubMed Web of Science ®Google Scholar
• Tuck SP, Data HK. Osteoporosis in the aging male: Treatment options. Clinical Interventions in Aging 2007; 2(4): 521–536.
   Web of Science ®Google Scholar
• Kelepouris N, Harper KD, Gannon F, Kaplan FS, Haddad JG. Severe osteoporosis in men. Ann Intern Med 1995; 123(6): 452–460.
   Web of Science ®Google Scholar
• Farmer ME, White LR, Brody JA, Bailey KR. Race and sex differences in hip frac-ture incidence, Am J Public Health 1984; 74(12): 1374–1380.
   PubMed Web of Science ®Google Scholar
• Haentjens P. Magaziner JS, Colón-Emeric CS, et al. Meta-analysis: excess mortal-ity after hip fracture among older women and men. Ann Intern Med 2010; 152: 380–390.
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353(9156): 878–882.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Cones; or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989; 149: 2445–2448.
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic frac-tures in elderly men. Am J Epidemio11996; 144: 255.
   PubMed Web of Science ®Google Scholar
• Autier P. Haentjens P. Bentin J, et al. Costs induced by hip fractures: a prospec-tive controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 2000; 11:373–380.
   PubMed Web of Science ®Google Scholar
• Body JJ, Bergmann P. Boonen S, et al. Evidence-based guidelines for the phar-macological treatment of postmenopausal osteoporosis: a consensus docu-ment by the Belgian Bone Club. Osteoporos Int 2010; 21(10): 1657–1680.
   Web of Science ®Google Scholar
• WHO publication - Kanis JA, on behalf of the World Health Organization Scien-tific Group. Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield 2007.
   Google Scholar
• hftp://www.shefac.uk/FRAX/index.jsp, accessed on 18 March 2011.
   Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Years Randomized Clinical Trial, JAMA 1999; 282, 637–646.
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Bruyere O, Cannata-Andia JB, et al. Management of osteoporosis in the elderly, Curr Med Res Opin 2009; 25(10): 2373–2387.
   PubMed Web of Science ®Google Scholar
• Boonen S, Bischoff-Ferrari HA, Cooper C, et al. Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evi-dence. Calcif Tissue Int 2006; 78(5): 257–270.
   PubMed Web of Science ®Google Scholar
• Boonen S, Dejaeger E, Vanderschueren D, Venken K, Bogaerts A, Verschueren S. Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective; Best Practice & Research Clinical Endocrinology & Metabolism 2008; 22: 765–785.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Optimal calcium intake. Conn Med 1994; 58: 613–623.
   Google Scholar
• Packaged insert Protelos® http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Productinformation/human/000560/WC500045525.pdf, accessed on 30 November 2010.
   Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teripara-tide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use, Endocr Rev 2005; 26: 688–703.
   PubMed Web of Science ®Google Scholar
• Packaged insert Aclaste® http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Productinformation/human/000595/WC500020940.pdf, accessed on 30 November 2010.
   Google Scholar
• Devogelaer JP, Goemaere S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006; 17(1): 8–19.
   PubMed Web of Science ®Google Scholar
• Perkins AC, Blackshaw PE, Hay PD, et al. Esophageal transit and in vivo disinte-gration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Clin Ther 2008; 30(5): 834–844.
   Web of Science ®Google Scholar
• Grima DT, Papaioannou A, Airia P. loannidis G, Adachi JD. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study; BMC Musculoskelet Disord 2010; 11–68.
   Google Scholar
• Ringe JD and Möller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmen-opausal osteoporosis: 1-year results of a retrospective patient chart review analysis, Rheumatol Int 2009; 30, 213–221.
   PubMed Web of Science ®Google Scholar
• Robert AA. Glucocorticoid-Induced Osteoporosis: Management Update. Curr Osteoporos Rep 2010; 8: 10–14.
   Google Scholar
• Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17(11): 1645–1652.
   Web of Science ®Google Scholar
• Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165(20): 2414–2419.
   PubMed Web of Science ®Google Scholar
• Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphos-phonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80(7): 856–861.
   PubMed Web of Science ®Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21(12): 1895–1903.
   PubMed Web of Science ®Google Scholar
• Kastelan D, Lozo P. Stamenkovic D, et al. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clin Rheumatol 2007; 28(3): 321–326.
   Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonates dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21(9): 1453–1460.
   PubMed Web of Science ®Google Scholar
• http://www.riziv.fgov.be/homenl.htm accessed on 18 march 2011.
   Google Scholar